A major long-term study, analyzing the health records of more than 650,000 adults in the United States, has found a possible link between some commonly prescribed medications for irritable bowel syndrome (IBS) and an increased risk of death. The research, published in the journal Communications Medicine, raises important questions about the long-term safety of these treatments.
Key takeaways
- Long-term use of antidepressants was associated with a 35% increased risk of death.
- Opioid-based antidiarrheal medications, such as loperamide and diphenoxylate, were associated with nearly doubling the risk of death.
- FDA-approved IBS medications and antispasmodics have not been shown to increase the risk of death.
- The study confirms that although the risks are statistically significant, the overall individual risk remains low.
Understanding the study results
Irritable bowel syndrome (IBS) is a chronic digestive disorder that affects about 10% of the United States population. Although there is no cure, management often includes dietary changes, behavioral therapies, and medications. Many patients are diagnosed at a young age and may use medications for years, yet most clinical trials evaluating these medications last less than a year, leaving a gap in understanding their long-term safety.
This comprehensive study, conducted by researchers at Cedars-Sinai University of Health Sciences, examined electronic health records spanning nearly two decades. She has researched the safety of various IBS treatments, including FDA-approved medications, antidepressants, antispasmodics, and opioid-based antidiarrheals such as loperamide and diphenoxylate.
High risks and important warnings
The analysis revealed that long-term use of antidepressants was associated with a 35% higher risk of death. Likewise, use of loperamide and diphenoxylate was associated with approximately double the risk of death compared with individuals not taking these medications. It is important to note that this study does not prove direct causality. The observed associations may reflect a greater likelihood of serious health complications, such as cardiovascular events, falls, or stroke, among those taking these medications.
Antidepressants, although not approved by the Food and Drug Administration specifically to treat IBS, are frequently prescribed to help manage pain and reduce the severity of symptoms. The study found no increase in the risk of death associated with other commonly recommended treatments such as IBS medications and FDA-approved antispasmodics.
Guidance for patients and health care providers
The researchers stressed that although the increased risks are statistically significant, the absolute risk for any individual patient remains low. They advise IBS patients not to panic but to be aware of these small but meaningful risks and discuss them with their health care providers when considering long-term treatment options. The study calls for more research to confirm these findings and identify at-risk patient groups, as well as future treatment guidelines to better address the long-term safety of IBS medications. An individualized approach to care is encouraged, focusing on underlying causes and safer, evidence-based options, rather than relying on one class of medication long-term.
